Yosprala
NDC Package 64950-424-30
Package Information
Yosprala is this combination product contains two medications: aspirin and omeprazole. Marketed by Genus Lifesciences Inc., this product is identified by NDC 64950-424 and is authorized under FDA application NDA205103.
Identification & Billing
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 64950 - Genus Lifesciences Inc.
- 64950-424 - Yosprala
- 64950-424-30 - 30 TABLET, FILM COATED in 1 BOTTLE
- 64950-424 - Yosprala
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Other Available Packages
The following commercial packages are registered under the same Product NDC (64950-424). Click a package code to view its specific billing and regulatory data.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 64950-424-30 identifies a specific commercial package of 30 tablet, film coated in 1 bottle of Yosprala, labeled by Genus Lifesciences Inc.. This product is billed for "EA" each discreet unit and contains an estimated amount of 30 billable units per package. This is formulated for use and contains as the active substance.
Is this product currently listed with the FDA?
This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Genus Lifesciences Inc. on March 04, 2019. The current certification is valid through September 25, 2020.
What are the primary indications for this medication?
This combination product contains two medications: aspirin and omeprazole. It is used to reduce the risk of stroke or heart attack in people who have had "mini-strokes" (transient ischemic attacks), or a stroke due to a blood clot, or who have heart disease. This product is used by people who are at risk for developing ulcers while taking aspirin. Aspirin belongs to a class of drugs known as antiplatelets. It has many uses, such as for pain relief or to reduce a fever. In low doses (such as this product), it is used to prevent harmful blood clots that can cause a stroke or heart attack. It works by stopping platelets in your blood from clumping together to form clots. Omeprazole belongs to a class of drugs known as proton pump inhibitors (PPIs). It works by decreasing the amount of acid your stomach makes. This effect helps prevent ulcers and other stomach-related problems (such as heartburn) that can be caused by aspirin. This medication contains a delayed-release form of aspirin. It should not be used to treat conditions that require an immediate-release form of aspirin, such as right after a heart attack or before certain heart procedures (such as percutaneous coronary intervention-PCI). Also, this combination product is not the same as taking aspirin and omeprazole separately.
How is this Genus Lifesciences Inc. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 64950042430. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 30 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.